Celldex Therapeutics (CLDX) Net Cash Flow (2010 - 2026)

Celldex Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 161.02% year-over-year to $6.8 million in Q1 2026; TTM through Mar 2026 was $18.6 million, a 118.97% increase from a year earlier, with the FY2025 full-year figure at $515000.0, up 107.97% from the prior year.
• Net Cash Flow grew to $6.8 million in Q1 2026 per CLDX's latest filing, from -$7.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $80.3 million in Q1 2024 and bottomed at -$72.3 million in Q2 2024.
• The 5-year median for Net Cash Flow is -$6.3 million (2024), against an average of -$201529.4.
• Across the five-year window, Net Cash Flow sank 933.3% in 2023 and soared 305.02% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at $10.8 million in 2022, then gained by 26.13% to $13.7 million in 2023, then plunged by 158.79% to -$8.0 million in 2024, then grew by 10.84% to -$7.2 million in 2025, then surged by 195.47% to $6.8 million in 2026.
• Per Business Quant, the three latest CLDX Net Cash Flow figures stand at $6.8 million (Q1 2026), -$7.2 million (Q4 2025), and $13.0 million (Q3 2025).